New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - bromocriptine mesilate 2.9mg equivalent to bromocriptine 2.5 mg (2.9 - 3.0 mg) - tablet - 2.5 mg - active: bromocriptine mesilate 2.9mg equivalent to bromocriptine 2.5 mg (2.9 - 3.0 mg) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - prolactin dependent menstrual cycle disorders (amenorrhoea, oligomenorrhoea, galactorrhoea), and/or female infertility associated with hyperprolactinaemia or luteal phase deficiency: · bromocriptine may normalise the menstrual cycle and/or induce ovulation without ovarian overstimulation. treatment with bromocriptine is not curative and it is not effective in treating ovarian failure.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg - tablet - 2.5 mg - active: bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg excipient: colloidal silicon dioxide disodium edetate dihydrate lactose monohydrate magnesium stearate maize starch maleic acid povidone

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg - tablet - 2.5 mg - active: bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg excipient: colloidal silicon dioxide disodium edetate dihydrate lactose monohydrate magnesium stearate maize starch maleic acid pregelatinised maize starch

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - bromocriptine mesilate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

focus pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - bromocriptine mesilate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - bromocriptine mesilate - oral tablet - 2.5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 2.87 mg (equivalent: bromocriptine, qty 2.5 mg) - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; disodium edetate; colloidal anhydrous silica; maleic acid; magnesium stearate - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - bromocriptine mesilate - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

the boots company plc - bromocriptine mesilate - oral tablet - 2.5mg